MLYS:NSD-Mineralys Therapeutics, Inc. Common Stock (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 15.7

Change

+0.12 (+0.77)%

Market Cap

N/A

Volume

0.41M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-02 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+1.05 (+0.24%)

USD 128.84B
REGN Regeneron Pharmaceuticals Inc

-2.95 (-0.60%)

USD 65.38B
ARGX argenx NV ADR

-8.00 (-1.37%)

USD 34.54B
ALNY Alnylam Pharmaceuticals Inc

-2.32 (-0.76%)

USD 32.75B
ONC BeiGene, Ltd.

+5.79 (+2.35%)

USD 27.70B
RPRX Royalty Pharma Plc

+0.03 (+0.09%)

USD 18.35B
SMMT Summit Therapeutics PLC

+2.90 (+16.33%)

USD 13.53B
INSM Insmed Inc

+1.40 (+1.95%)

USD 11.84B
INCY Incyte Corporation

+1.80 (+2.76%)

USD 11.42B
BMRN Biomarin Pharmaceutical Inc

-0.26 (-0.46%)

USD 11.29B

ETFs Containing MLYS

BBC Virtus LifeSci Biotech Cl.. 1.50 % 0.79 %

+0.64 (+3.37%)

USD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 27.54% 83% B 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.54% 83% B 88% B+
Trailing 12 Months  
Capital Gain 20.03% 80% B- 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.03% 80% B- 76% C+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 4.77% 58% F 57% F
Dividend Return 4.77% 58% F 54% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 26.83% 90% A- 65% D
Risk Adjusted Return 17.79% 78% C+ 55% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector